Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 123

Results For "IP"

10294 News Found

Biogen unveils promising new data for Salanersen in kids with SMA
News | March 14, 2026

Biogen unveils promising new data for Salanersen in kids with SMA

Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains


Zydus receives USFDA approval for cevimeline hydrochloride capsules
Drug Approval | March 14, 2026

Zydus receives USFDA approval for cevimeline hydrochloride capsules

Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sjögren’s syndrome.


Single-use gloves misused across India, raising health risks
Healthcare | March 14, 2026

Single-use gloves misused across India, raising health risks

One task, one interaction, one pair, experts advocate


Aster DM bags overwhelming shareholder backing for merger with Quality Care
Healthcare | March 14, 2026

Aster DM bags overwhelming shareholder backing for merger with Quality Care

The endorsement follows overwhelming support for the share swap preceding the merger,


Natural Biogenex joins forces with Fermbox Bio to boost fermentation-based biomanufacturing
Biotech | March 14, 2026

Natural Biogenex joins forces with Fermbox Bio to boost fermentation-based biomanufacturing

The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand


Wanbury bags key Brazil nod, eyes market expansion
News | March 14, 2026

Wanbury bags key Brazil nod, eyes market expansion

Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA


Middle East conflict pushes health systems to brink as casualties, displacement surge: WHO
Public Health | March 14, 2026

Middle East conflict pushes health systems to brink as casualties, displacement surge: WHO

The conflict is also triggering a widening public health emergency


Jubilant Ingrevia acquires Remidex Pharma for Rs 16.5 crore
News | March 14, 2026

Jubilant Ingrevia acquires Remidex Pharma for Rs 16.5 crore

Remidex manufactures micronutrient premixes and nutraceuticals,


APL Healthcare’s Unit-IV classified as VAI by the USFDA
News | March 14, 2026

APL Healthcare’s Unit-IV classified as VAI by the USFDA

This inspection is now closed